Acute Ischemic Stroke Articles & Analysis
11 news found
FDA Fast Track Designation for the prevention of stroke in patients after a non-cardioembolic ischemic stroke, which was granted in 2022. ...
ByBayer AG
Oodatroltide addresses the needs of more than 70% of acute ischemic stroke (AIS) patients who are either ineligible to receive proper therapy or are dissatisfied with the treatment outcome. The drug improves stroke treatment rates while expanding treatment coverage, providing neuroprotection, and reducing irreversible damage to ...
The PACIFIC-STROKE2 and PACIFIC-AMI3 Phase IIb trials compared the safety and efficacy of asundexian with placebo in patients following acute non-cardioembolic ischemic stroke or acute myocardial infarction (AMI), respectively. ...
ByBayer AG
In clinical studies, when dosed up to four times daily, TSC has been demonstrated safe and tolerable in more than 180 patients included in trials across a variety of indications including patients with glioblastoma multiforme brain cancer (“GBM”), peripheral artery disease with intermittent claudication, stroke, and COVID-19. In pre-clinical data, TSC has been ...
ByCervoMed
The European Stroke Organization has chosen “Sonothrombolysis in Patients With Acute Ischemic Stroke With Large Vessel Occlusion: An Individual Patient Data Meta-Analysis” for the September 2021 “Paper of the ...
This prospective, multi-center clinical trial is the first study designed to evaluate the clinical benefits of direct aspiration for the treatment of ischemic stroke with the Zoom 88 Large Distal Platform, which is currently FDA cleared for neurovascular access. Additionally, the trial will gather data on the clinical benefits of the full Zoom ...
Stroke has published “Sonothrombolysis in Patients With Acute Ischemic Stroke With Large Vessel Occlusion: An Individual Patient Data Meta-Analysis”. ...
Therapeutic Advances in Neurological Disorders has published “Endovascular equipoise shift in a phase III randomized clinical trial of sonothrombolysis for acute ischemic stroke”. This paper presents a case study of the CLOTBUST-ER trial, showing that the “increasing implementation of endovascular therapies across major academic ...
Imperative Care, Inc., a company singularly dedicated to answering unsolved problems in stroke, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s ZOOM™ Aspiration System – a family of products designed to facilitate clot removal during ischemic stroke. ...
Though the trial did not meet its primary endpoint, the article and accompanying independent commentary offer a cogent review of the obstacles and shortcomings which may have impaired the CLOTBUST-ER trial, and highlights the continued promise of sonothrombolysis as a safe and effective option for acute ischemic stroke treatment. The publication ...
Wilder was President and CEO of PhotoThera, Inc., a company that was developing a unique therapy for acute ischemic stroke patients. Prior to this, Mr. Wilder served as President and CEO of Micro Therapeutics, Inc. ...